Search
AstraZeneca's Imfinzi Approved in China for Limited-Stage Small Cell Lung Cancer
2025-06-04 /
Read about 0 minute
Author：小编
AstraZeneca has announced the approval of its drug Imfinzi (durvalumab) by the National Medical Products Administration of China. This approval grants durvalumab as a monotherapy option for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced progression following platinum-based chemoradiotherapy. This development presents a novel therapeutic choice for these patients.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
